3-(4-Formyl-1H-pyrazol-1-YL)propanenitrile | 1006518-87-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(4-Formyl-1H-pyrazol-1-YL)propanenitrile
• 英文别名: 3-(4-formylpyrazol-1-yl)propanenitrile
• CAS: 1006518-87-1
• 化学式: C₇H₇N₃O
• 分子量: 149.15
• InChiKey: JKAVMKREHIBQFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Spiro bicyclic inhibitors of menin-MLL interaction
  申请人：Janssen Pharmaceutica NV

  公开号：US11220517B2

  公开（公告）日：2022-01-11

  The present invention relates to compounds of formula (I): wherein the variables have the meaning defined in the Specification. The compounds according to the present invention are useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

  本发明涉及式（I）化合物： 其中的变量具有说明书中定义的含义。根据本发明的化合物可用于哺乳动物的治疗和/或预防，特别是螺环双环化合物、包含此类化合物的药物组合物，以及它们作为 menin/MLL 蛋白/蛋白相互作用抑制剂的用途，可用于治疗癌症、骨髓增生异常综合征（MDS）和糖尿病等疾病。
• SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION
  申请人：Janssen Pharmaceutica NV

  公开号：US20190211036A1

  公开（公告）日：2019-07-11

  The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.